Skip to main content
Premium Trial:

Request an Annual Quote

Germany's Mosaiques Collaborating with FDA on Drug Toxicity Biomarkers

NEW YORK (GenomeWeb News) – German firm Mosaiques Diagnostics and Therapeutics has inked a contract with the US Food and Drug Administration to collaborate on the discovery and validation of biomarkers for assessing drug toxicity.

Under the partnership, the FDA will provide information about drugs, expected toxicities, and animal studies. Mosaiques will contribute its proteome analysis expertise, particularly in sample preparation of urine and capillary electrophoresis coupled mass spectrometry.

"We are aiming to reduce or even prevent adverse effects of drugs by implementing our technology in preclinical testing," Mosaiques Founder and CSO Harald Mischak, said in a statement. "This agreement with the FDA underlines the potential of the protein pattern technology for modern medicine and appropriate treatment."

Further terms of the collaboration were not disclosed.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.